# Evaluation of 626 in Healthy Adult Subjects

> **NCT06674525** · PHASE1 · RECRUITING · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Healthy Subjects (HS)

## Interventions

- **DRUG:** 626
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06674525
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-02
- **Primary completion:** 2025-06
- **Final completion:** 2025-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06674525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06674525, "Evaluation of 626 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06674525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*